Cargando…
Arterial hypertension management with conversion enzyme inhibitors in hemodialysis patients
By establishing the renal suppletion procedure, the patients with chronic renal failure also have an acceleration of arterial hypertension phenomena. The management of this situation calls for the understanding of the ethological mechanisms (hypervolemia by the reduction of Na excretion and high ren...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Carol Davila University Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3019039/ https://www.ncbi.nlm.nih.gov/pubmed/20302199 |
_version_ | 1782196150565076992 |
---|---|
author | Costea, AC Costea, DO David, C Grasa, CN |
author_facet | Costea, AC Costea, DO David, C Grasa, CN |
author_sort | Costea, AC |
collection | PubMed |
description | By establishing the renal suppletion procedure, the patients with chronic renal failure also have an acceleration of arterial hypertension phenomena. The management of this situation calls for the understanding of the ethological mechanisms (hypervolemia by the reduction of Na excretion and high rennin secretion) and the adaptation of the therapeutic approach to every patient. An individualized dialysis prescription is imposed, taking into account the residual renal function and an anti–hypertension treatment, in which the role of the conversion enzyme inhibitors (ACE inhibitor) is intensely debated. |
format | Text |
id | pubmed-3019039 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Carol Davila University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-30190392011-03-03 Arterial hypertension management with conversion enzyme inhibitors in hemodialysis patients Costea, AC Costea, DO David, C Grasa, CN J Med Life General Article By establishing the renal suppletion procedure, the patients with chronic renal failure also have an acceleration of arterial hypertension phenomena. The management of this situation calls for the understanding of the ethological mechanisms (hypervolemia by the reduction of Na excretion and high rennin secretion) and the adaptation of the therapeutic approach to every patient. An individualized dialysis prescription is imposed, taking into account the residual renal function and an anti–hypertension treatment, in which the role of the conversion enzyme inhibitors (ACE inhibitor) is intensely debated. Carol Davila University Press 2010-02-15 2010-02-25 /pmc/articles/PMC3019039/ /pubmed/20302199 Text en ©Carol Davila University Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | General Article Costea, AC Costea, DO David, C Grasa, CN Arterial hypertension management with conversion enzyme inhibitors in hemodialysis patients |
title | Arterial hypertension management with conversion enzyme
inhibitors in hemodialysis patients
|
title_full | Arterial hypertension management with conversion enzyme
inhibitors in hemodialysis patients
|
title_fullStr | Arterial hypertension management with conversion enzyme
inhibitors in hemodialysis patients
|
title_full_unstemmed | Arterial hypertension management with conversion enzyme
inhibitors in hemodialysis patients
|
title_short | Arterial hypertension management with conversion enzyme
inhibitors in hemodialysis patients
|
title_sort | arterial hypertension management with conversion enzyme
inhibitors in hemodialysis patients |
topic | General Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3019039/ https://www.ncbi.nlm.nih.gov/pubmed/20302199 |
work_keys_str_mv | AT costeaac arterialhypertensionmanagementwithconversionenzymeinhibitorsinhemodialysispatients AT costeado arterialhypertensionmanagementwithconversionenzymeinhibitorsinhemodialysispatients AT davidc arterialhypertensionmanagementwithconversionenzymeinhibitorsinhemodialysispatients AT grasacn arterialhypertensionmanagementwithconversionenzymeinhibitorsinhemodialysispatients |